Status:
COMPLETED
Effect of Rosiglitazone in Nondiabetic Patients With the Metabolic Syndrome
Lead Sponsor:
University of Colorado, Denver
Conditions:
Metabolic Syndrome
Insulin Resistance
Eligibility:
All Genders
30-55 years
Phase:
PHASE4
Brief Summary
The metabolic syndrome is a collection of health risks that includes obesity, high blood pressure, high triglycerides, high blood sugar, low good cholesterol, and resistance to insulin. The purpose of...
Eligibility Criteria
Inclusion
- Nondiabetic subjects with an NCEP/ATP III diagnosis of the metabolic syndrome
Exclusion
- Statin Medications, liver disease, cardiovascular disease, heart failure, diabetes, chronic kidney disease,
Key Trial Info
Start Date :
November 1 2004
Trial Type :
INTERVENTIONAL
End Date :
October 1 2006
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00364221
Start Date
November 1 2004
End Date
October 1 2006
Last Update
November 22 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Colorado at Denver and Health Sciences Center General Clinical Research Center
Denver, Colorado, United States, 80262